GlassScriptPhysician profile
Asad A Rizvi
NPI 1912907346
$4,650.20
in general payments reported to CMS, 2019-2025
24 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $1,607 · 2021: $295 · 2022: $458 · 2023: $294 · 2024: $385 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,816.12 | 2020-2022 | |
| Edwards Lifesciences Corporation | $1,198.87 | 2019 | |
| Medtronic, INC. | $662.06 | 2021-2025 | Corevalve Evolut R |
| Bard Peripheral Vascular, INC. | $146.14 | 2019 | |
| Angiodynamics, INC. | $128.88 | 2023 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $93.77 | 2020-2024 | Nc Trek Neo |
| Penumbra, INC. | $83.76 | 2023-2024 | Penumbra System, Indigo System |
| Shockwave Medical, INC | $67.09 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.69 | 2022-2025 | Entyvio, Gattex |
| Cardiva Medical, INC. | $51.91 | 2024 | Savvywire, Optowire |
| Janssen Pharmaceuticals, INC | $44.92 | 2020-2024 | Xarelto |
| Madrigal Pharmaceuticals | $32.60 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $29.68 | 2024 | Bridion |
| Medtronic Vascular, INC. | $29.38 | 2019 | |
| Amgen INC. | $27.08 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.93 | 2019 | |
| Chiesi USA, INC. | $21.77 | 2023 | Kengreal |
| Terumo Medical Corporation | $20.82 | 2022 | |
| Intercept Pharmaceuticals, INC. | $20.54 | 2024 | |
| Biotronik INC. | $20.25 | 2022 | |
| Opsens INC. | $20.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.85 | 2021 | |
| Biomerieux INC | $15.02 | 2023 | |
| Ge Healthcare | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.